LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

Kodu・Aktsiate loetelu・Galectin Therapeutics Inc

Galectin Therapeutics Inc

Suletud

SektorTervishoid

5.94 8.99

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

5.45

Max

6.04

Põhinäitajad
By Trading Economics
Sissetulek	2.1M -7.5M
Kasumimarginaal	-33,241.667
Töötajad	15
EBITDA	4.5M -5.7M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+8.89% upside

Turustatistika
By TradingEconomics
Turukapital	90M 335M
Eelmine avamishind	-3.05
Eelmine sulgemishind	5.94

Uudiste sentiment

By Acuity

60%

40%

320 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

1.19 / 1.33 Toetus ja vastupanu

Galectin Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

17. nov 2025, 18:59 UTC

Suurimad hinnamuutused turgudel

Medicus Pharma Shares Rise After Filing of FDA Priority-Voucher Application

17. nov 2025, 23:40 UTC

Market Talk

Gold Consolidates Amid Mixed Signals -- Market Talk

17. nov 2025, 23:34 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

17. nov 2025, 22:58 UTC

Market Talk

RBA's Easing Cycle Is Done, TD Securities Says -- Market Talk

17. nov 2025, 22:46 UTC

Market Talk

Risk Assets Set to Have a Strong 2026 -- Market Talk

17. nov 2025, 22:06 UTC

Omandamised, ülevõtmised, äriostud

Constellation Software's Harris Operating Group Completes Agreement To Acquire TECVIA Holding GmbH >CSU.T

17. nov 2025, 22:02 UTC

Tulu

Trip.com Group 3Q Rev $2.6B >TCOM

17. nov 2025, 22:02 UTC

Tulu

Trip.com Group 3Q Adj EPS $3.87 >TCOM

17. nov 2025, 22:02 UTC

Tulu

Trip.com Group 3Q EPS $4.02 >TCOM

17. nov 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17. nov 2025, 21:40 UTC

Tulu

James Hardie Industries 2Q Adj EPS 26c >JHX

17. nov 2025, 21:40 UTC

Tulu

James Hardie Industries 2Q Loss/Shr 10c >JHX

17. nov 2025, 21:39 UTC

Tulu

James Hardie Industries 2Q Sales $1.29B >JHX

17. nov 2025, 21:38 UTC

Tulu

Omandamised, ülevõtmised, äriostud

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17. nov 2025, 21:38 UTC

Tulu

XPeng Earnings Beat Wall Street Estimates. Why the Stock Is Falling. -- Barrons.com

17. nov 2025, 21:10 UTC

Tulu

XP Inc. 3Q EPS BRL2.47 >XP

17. nov 2025, 21:10 UTC

Tulu

XP Inc. 3Q Rev BRL4.67B >XP

17. nov 2025, 20:20 UTC

Market Talk

U.S. Natural Gas Retreats on Milder Weather Outlook -- Market Talk

17. nov 2025, 20:12 UTC

Market Talk

Easing Underlying Inflation in Canada Seen Leaving Door Open to Rate Cuts Next Year -- Market Talk

17. nov 2025, 20:12 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. nov 2025, 20:09 UTC

Market Talk

Latest Canadian Inflation Data Supports View BoC is Done Cutting Rates This Cycle -- Market Talk

17. nov 2025, 19:29 UTC

Market Talk

Gold Slide Continues to Start Week -- Market Talk

17. nov 2025, 19:16 UTC

Tulu

Omandamised, ülevõtmised, äriostud

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17. nov 2025, 18:20 UTC

Omandamised, ülevõtmised, äriostud

Johnson & Johnson Will Buy Cancer Drugmaker Halda Therapeutics for $3.1 Billion -- Barrons.com

17. nov 2025, 16:45 UTC

Omandamised, ülevõtmised, äriostud

Oil Giant TotalEnergies Is Betting Big on Electricity -- Update

17. nov 2025, 16:16 UTC

Tulu

Omandamised, ülevõtmised, äriostud

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17. nov 2025, 16:15 UTC

Tulu

Luckin, a Chinese Challenger to Starbucks, Aims to Return to U.S. Stock Market -- WSJ

17. nov 2025, 15:40 UTC

Omandamised, ülevõtmised, äriostud

Strategy Is in the Crosshairs of Crypto Investors. It Bought More Bitcoin Anyway. -- Barrons.com

17. nov 2025, 15:22 UTC

Omandamised, ülevõtmised, äriostud

Alphabet Stock Pops After Berkshire Takes Stake. Why Buffett Might Be Buying. -- Barrons.com

17. nov 2025, 15:19 UTC

Market Talk

Deutsche Bank's Strategic Plan Looks a Tad Underwhelming -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Galectin Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

8.89% tõus

12 kuu keskmine prognoos

Keskmine 6 USD 8.89%

Kõrge 6 USD

Madal 6 USD

Põhineb 1 Wall Streeti analüütiku instrumendi Galectin Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Galectin Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.19 / 1.33Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

Sentiment

By Acuity

320 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Galectin Therapeutics Inc

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.